Published in N Engl J Med on September 20, 2012
Believe the data. N Engl J Med (2012) 2.20
Declaration and Handling of Conflicts of Interest in Guidelines: A Study of S1 Guidelines From German Specialist Societies From 2010-2013. Dtsch Arztebl Int (2015) 1.68
Increasing enrollment in drug trials: the need for greater transparency about the social value of research in recruitment efforts. Mayo Clin Proc (2013) 1.28
Taking financial relationships into account when assessing research. Account Res (2013) 1.00
Do cardiology quality measures actually improve patient outcomes? J Am Heart Assoc (2014) 0.95
Effect of physician disclosure of specialty bias on patient trust and treatment choice. Proc Natl Acad Sci U S A (2016) 0.95
Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications. BMC Med (2014) 0.92
Conflict of interest disclosure in biomedical research: A review of current practices, biases, and the role of public registries in improving transparency. Res Integr Peer Rev (2016) 0.86
Disclosing conflicts of interest in patient decision aids. BMC Med Inform Decis Mak (2013) 0.86
The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis. Trials (2017) 0.80
Publication and non-publication of drug trial results: a 10-year cohort of trials in Norwegian general practice. BMJ Open (2016) 0.78
A retrospective analysis of reported errata in five leading medical journals in 2012. J Community Hosp Intern Med Perspect (2014) 0.78
How physicians interpret research funding disclosures. N Engl J Med (2012) 0.75
How physicians interpret research funding disclosures. N Engl J Med (2012) 0.75
Effect of different financial competing interest statements on readers' perceptions of clinical educational articles: study protocol for a randomised controlled trial. BMJ Open (2016) 0.75
Research participant compensation: A matter of statistical inference as well as ethics. Contemp Clin Trials (2015) 0.75
Conflicts of interest in research: looking out for number one means keeping the primary interest front and center. Curr Rev Musculoskelet Med (2015) 0.75
Regulatory science: Trust and transparency in clinical trials of medical devices. Nat Rev Cardiol (2015) 0.75
Impact of adding a limitations section to abstracts of systematic reviews on readers' interpretation: a randomized controlled trial. BMC Med Res Methodol (2014) 0.75
The relationship between the physician and pharmaceutical industry: background ethics and regulation proposals. Croat Med J (2016) 0.75
Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. PLoS One (2016) 0.75
Perceived conflict of interest in health science partnerships. PLoS One (2017) 0.75
Do We Care? Should We? Am J Sports Med (2016) 0.75
Wearable Technologies in Collegiate Sports: The Ethics of Collecting Biometric Data From Student-Athletes. Am J Bioeth (2017) 0.75
Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance. BMJ Open (2017) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
Response rates to mail surveys published in medical journals. J Clin Epidemiol (1997) 21.55
Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med (2008) 19.86
Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (2003) 18.72
Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA (2003) 16.08
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA (2008) 12.36
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77
The ClinicalTrials.gov results database--update and key issues. N Engl J Med (2011) 9.83
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA (2003) 8.21
Reengineering translational science: the time is right. Sci Transl Med (2011) 7.55
Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med (1982) 7.14
Impugning the integrity of medical science: the adverse effects of industry influence. JAMA (2008) 6.74
Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med (2006) 6.66
A national survey of physician-industry relationships. N Engl J Med (2007) 6.63
Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA (2012) 6.56
Funding of US biomedical research, 2003-2008. JAMA (2010) 5.33
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA (2006) 3.65
Does declaration of competing interests affect readers' perceptions? A randomised trial. BMJ (2002) 3.44
Do self- reported intentions predict clinicians' behaviour: a systematic review. Implement Sci (2006) 2.93
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Participation of academic scientists in relationships with industry. Health Aff (Millwood) (2009) 2.22
A trial of disclosing physicians' financial incentives to patients. Arch Intern Med (2006) 1.91
Patient-Centered Outcomes Research Institute: the intersection of science and health care. Sci Transl Med (2010) 1.89
Does the type of competing interest statement affect readers' perceptions of the credibility of research? Randomised trial. BMJ (2004) 1.84
Physician professionalism and changes in physician-industry relationships from 2004 to 2009. Arch Intern Med (2010) 1.81
Industry-sponsored clinical research: a broken system. JAMA (2008) 1.80
Postmarketing surveillance--lack of vigilance, lack of trust. JAMA (2004) 1.78
Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials. J Clin Oncol (2010) 1.73
Journal reading habits of internists. J Gen Intern Med (2000) 1.63
Toward more uniform conflict disclosures--the updated ICMJE conflict of interest reporting form. N Engl J Med (2010) 1.52
A model for dissemination and independent analysis of industry data. JAMA (2011) 1.35
Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol (2008) 1.33
Failure to discount for conflict of interest when evaluating medical literature: a randomised trial of physicians. J Med Ethics (2010) 1.22
The role of conflict of interest in reporting of scientific information. Chest (2009) 1.18
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. Am Heart J (2012) 1.17
Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med (2007) 1.14
Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research. BMC Res Notes (2011) 1.13
Attitudes of academic and clinical researchers toward financial ties in research: a systematic review. Sci Eng Ethics (2005) 1.10
The money blind: how to stop industry bias in biomedical science, without violating the First Amendment. Am J Law Med (2011) 0.86
JUPITER clinical directions--polling results. N Engl J Med (2009) 0.85
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
Addressing the ethical challenges in genetic testing and sequencing of children. Am J Bioeth (2014) 7.34
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Patient Perspectives on the Learning Health System: The Importance of Trust and Shared Decision Making. Am J Bioeth (2015) 5.07
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 4.99
Bench to bedside: mapping the moral terrain of clinical research. Hastings Cent Rep (2008) 4.98
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
Equipoise and the dilemma of randomized clinical trials. N Engl J Med (2011) 4.34
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07
Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
Clinical trials and medical care: defining the therapeutic misconception. PLoS Med (2007) 3.77
Attitudes Toward Risk and Informed Consent for Research on Medical Practices: A Cross-sectional Survey. Ann Intern Med (2015) 3.71
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95
Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clin Trials (2008) 2.94
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Internet marketing of herbal products. JAMA (2003) 2.77
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation (2003) 2.73
Point-counterpoint. Ethics and genomic incidental findings. Science (2013) 2.73
The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med (2010) 2.71
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
Sending pharma better signals. Science (2005) 2.69
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA (2011) 2.60
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring) (2009) 2.56
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med (2015) 2.53
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52